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Abstract 
 
Lower limb neuropathic pain in HIV patients is a common manifestation of sensory neuropathy (HIV-
SN), but can be seen in patients who do not meet standard definitions of HIV-SN. The drug stavudine 
is a risk factor for HIV-SN, but some patients treated without stavudine experience HIV-SN, and the 
prevalence and risk factors influencing neuropathic pain in this setting are unknown. A cross sectional 
study at Cipto Mangunkusumo Hospital Jakarta tested 197 HIV patients treated for >12 months 
without stavudine.  HIV-SN was defined using the AIDS Clinical Trial Group Brief Peripheral 
Neuropathy Screening Test (ACTG-BPNST). A validated Indonesia translation of Douleur 
Neuropathique en 4 (DN4) questionnaire was used to assess lower limb neuropathic pain. Nerve 
conduction studies assessed large nerve fiber function and Stimulated Skin Wrinkle (SSW) tests were 
performed to assess small nerve fibers. The prevalence of neuropathic pain was 6.6%. BPNST+HIV-SN 
was diagnosed in 14.2% of the cohort and 38.5% of patients with pain. Use of protease inhibitors and 
ART duration <2 years associated with neuropathic pain in univariate (p=0.036, p=0.002, resp.) and 
multivariable analyses (model p<0.001). SSW tests were abnormal in 53.8% of subjects with 
neuropathic pain and only 25.5% without pain (p=0.05). Patients with pain without BPNST+HIV-SN had 
begun ART more recently than those with both diagnoses. Overall this preliminary study showed that 
neuropathic pain associated with protease inhibitors and a shorter duration of ART in Indonesian HIV 
patients, and may be an early symptom of small fiber neuropathy in this context. 
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Introduction 
 
Neuropathic pain (NP) is a common symptom of sensory neuropathy in HIV patients (HIV-SN), 
occurring both in anti-retroviral therapy (ART) naïve patients(1) and among those using ART. NP can 
affect the adherence to ART and influence the quality of life (2), Nucleoside reverse transcriptase 
inhibitors (NRTI) such as stavudine (3), and Protease Inhibitors (PI) (4), have been associated with HIV-
SN, but their role in NP is less clear. In our studies assessing HIV-SN by AIDS Clinical Trial Group Brief 
Peripheral Neuropathy Screening Tool (ACTG-BPNST), the prevalence of HIV-SN halved between 2006 
when all patients received stavudine (observed associations with HIV-SN were increasing age and 
height) and 2016 when this drug was no longer used. HIV-SN was then associated with ongoing HIV 
replication (5). 
 
NP occurs in diverse clinical syndromes and has been linked with damage to small myelinated fibers 
or unmyelinated C-fibers [reviewed in (6)]. There is evidence that HIV may damage large myelinated 
fibers, with CD4+ T-cell counts correlating inversely with abnormal nerve conduction velocity in one 
study (7). In the same cohort, the duration of neurotoxic ART correlated with an abnormal 
Sympathetic Skin Response, reflecting damage to thin unmyelinated sympathetic nerve fibers and 
with reduced intraepithelial nerve fiber densities evident histologically (8).  
 
We present a preliminary study assessing associations between NP and clinical factors, demographics, 
and small and large nerve fiber function in clinic patients with HIV receiving modern (stavudine 
sparing) ART regimens.  
 
Methods 
 
HIV-positive adults who had used ART for at least 12 months but who had never been exposed to 
stavudine were screened for neuropathy and neuropathic pain at the Integrated HIV Care Clinic, Cipto 
Mangunkusumo Hospital, Jakarta, Indonesia. Potential participants were screened by selecting from 
medical record of HIV patients who had attended the clinic for at least 1 year. Patients with any 
history of other conditions linked with a neuropathy (e.g. diabetes mellitus, Leprae, history of 
Guillain-Barré Syndrome, malignancy, radiculopathy) or unable to provide informed consent were 
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excluded. Sensory neuropathy was assessed by a neurologist (FO) and a general practitioner (DDS) 
who had been trained by FO using the AIDS Clinical Trials Group Brief Peripheral Neuropathy Screen 
Tool (ACTG-BPNST), and defined as present if the individual had one or more of the lower limb 
neuropathic symptoms (1 positive subjective symptom), plus absent ankle reflexes or reduced 
vibration sense at the great toe (positive objective sign). NP was defined as shooting, stabbing, sharp 
or burning pain of bilateral lower limbs and assessed using The Douleur Neuropathique en 4 (DN4) 
questionnaire that has been translated and validated in the Indonesian language (9).   A numeric 
rating scale (NRS) was used to assess pain severity. Pain was classified as mild (NRS≤5), moderate 
(NRS=6-7), or severe (NRS≥8). The study was approved by the Ethics Committee of the Faculty of 
Medicine, Universitas Indonesia (579/UN2.F1/ETIK/2014). All participants gave written informed 
consent. 
 
Stimulated Skin Wrinkling (SSW) tests used eutectic mixture of local anesthetic cream contained 2.5% 
lidocaine and 2.5% prilocaine to assess the function of small peripheral nerve fibers.  SSW was 
performed on both hands. The cut-off point defining a normal response was 3 degrees of skin 
wrinkling. SSW was assessed as abnormal if both hands were affected (10). Nerve conduction studies 
(NCS) were performed by a neurologist (FO) and assessed motor and sensory nerves in the upper and 
lower limbs using a Sierra-Summit Cadwell® instrument. Motor function was assessed bilaterally in 
the common peroneal and tibial nerves, right median and ulnar nerves. Antidromic sensory 
conduction was assessed in medial, ulnar, peroneal superficial and sural nerves. NCS was defined as 
abnormal if one or more of amplitude, distal latency or conduction velocity was abnormal bilaterally 
compared to normal values derived in our clinic.  
 
Patient height and weight were measured during the study assessment and clinical data were 
collected from medical files. Plasma HIV RNA was measured using a Cobas Amplicor Monitor (Roche 
Molecular Diagnostics, Pleasanton, CA).  
 
Statistical analyses utilized SPSS version 21.0 and GraphPad Prism 7.0.  Demographic, clinical and 
treatment details of patients with and without neuropathy were compared using Fisher’s exact tests 
(dichotomous variables), Mann-Whitney tests [non-parametric data, described using median (range)] 
or unpaired t tests [parametric data, described using mean + SD] and Spearman’s correlations (non-
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parametric continuous variables).  Multivariable analyses were undertaken using logistic regression 
modeling (including all factors with p<0.25 on univariate analysis) with a stepwise removal procedure.  
 
Results 
  
From 2596 HIV patients, 907 met inclusion criteria – including ART without stavudine for 12 months. 
However, of eligible patients, only 197 patients gave their consent. Patient selection is described in 
Supplementary Figure 1. These individuals were screened as described above. We identified 13 
subjects (6.6%) with NP and 28 (14.2%) with HIV-SN assessed by BPNST (BPNST+HIV-SN). Eight among 
13 subjects with NP had symptoms consistent with sensory neuropathy (positive subjective signs) 
with normal tendon reflexes and normal vibration tests (negative objective signs). The remaining 5 
subjects were BPNST+HIV-SN+.  
 
Univariate associations with NP are presented in Table 1. The presence of NP associated with use of a 
protease inhibitor (PI; Lopinavir/Ritonavir), shorter ART duration (median 1.7 (1-6.4) years), the 
presence of BPNST+HIV-SN or an abnormal SSW test (p<0.05). Isoniazid use and alcohol consumption 
were not associated risk factors of NP. We observed a low rate of abnormal NCS in this cohort (6.5%) 
and all patients with NP had normal NCS data. Multivariable analyses tested all factors that achieved 
p<0.25 in univariate analysis, followed by a stepwise removal procedure. PI use [OR (95%CI): 4.4(1.2-
16), p=0.02] and ART duration <2 years [OR (95%CI): 6.9 (2.1-23), p=0.002] were independently 
associated with NP and created a significant model (R2=0.18, p<0.001).  
 
Pain was described as mild in 4 subjects and moderate-severe in 9 subjects. We noted negative 
correlations between pain score and nadir CD4+ T-cell count (r= -0.75, p=0.003) or current CD4+ T-cell 
count (r= -0.64, p=0.017). Accordingly, median nadir and current CD4+ T-cell counts were lower in 
patients with moderate-severe NP (54 vs. 309 cell/L; p=0.006 and 242 vs. 527 cell/L; p=0.011, 
respectively) than those with mild NP. Neither PI use nor ART duration associated with pain severity 
(p=0.65).  
 
As indication whether pain precedes BPNST+HIV-SN, we assessed time on ART.  Patients with NP 
without BPNST+HIV-SN had been on ART for a shorter period than those with NP and BPNST+HIV-SN 
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(p=0.03) or BPNST+HIV-SN only (p=0.0009). The latter two groups had received ART for a similar time 
(p=0.2) (Figure 1). 
 
Discussion 
 
The prevalence of NP is 20.9% among ART naïve HIV patients (11) and about 14.3% in HIV patients on 
ART with stavudine (12). Here the prevalence of NP was lower in patients treated without stavudine. 
Unfortunately, we have no equivalent data to assess whether NP is more common in our patient 
cohort than the general population of Jakarta. A meta-analysis (13) presents French, Brazilian and 
Canadian studies with a high prevalence of pain (7-18%) assessed with DN4 but notes that all were 
postal or telephone surveys. Some or all may include traumatic nerve injury, arthritic pain and post-
herpetic pain, so the question of what is “normal” remains unresolved. 
 
PI-based ART was independently associated with NP in our study and has been associated with HIV-SN 
previously (3). We saw only a marginal association between CD4+ T-cell counts and prevalent NP 
(p=0.09), but there was a clearer association between lower nadir and current CD4+ T-cell count and 
moderate-severe pain in patients with NP.  Low CD4+ T-cell counts are associated with systemic 
immune activation and associated inflammation around peripheral nerves. We recently demonstrated 
chemokine receptors expressed by CD14+ and CD3+ cells infiltrating tissues around damaged 
cutaneous nerves in HIV-SN patients (14).  
 
Isoniazid is well known as a factor associated with peripheral neuropathy. Co-administration of 
isoniazid and stavudine increased incidence of HIV-SN when compared the use of stavudine alone (15) 
but in this cohort of patients with no exposure to stavudine, isoniazid was not associated with HIV-SN 
(5) or NP. High levels alcohol consumption is a risk factor of neuropathy (16) but was not associated 
with NP in this study. However, we didn’t assess the quantity and type of alcohol consumed. 
Anecdotally, consumption is rarely high, but it may be under reported in the predominantly Muslim 
population of Jakarta.  
 
Here 5/13 NP subjects were assessed as HIV-SN by BPNST. The DN4 questionnaire includes the 
assessment of small fiber nerves (pin-prick test) while the BPNST also assesses the large fiber nerve 
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(deep tendon reflex, vibration test). Therefore, patients who only had small fiber nerve impairment 
might have negative result on BPNST. Accordingly, NCS were normal in all patients with NP in our 
study, consistent with small fibers being invisible to NCS. On the other hand, abnormalities in SSW did 
associate with NP in this cohort.  SSW is a simple way to diagnose small fiber neuropathy in HIV 
patients with sensitivity of 60% and specificity of 67% compare to BPNST (17).  Wrinkling of the 
fingertips results from vasoconstriction controlled by sympathetic fibers. It has been used to establish 
small fiber damage in diabetes and approaches the sensitivity of intraepidermal nerve fiber density 
(10).  
 
Patients with NP who did not meet the criteria for a diagnosis of HIV-SN by BPNST had begun ART 
more recently than those with HIV-SN, so NP may be an early sign of HIV-SN, occurring before clinical 
signs assessed using the BPNST. Indeed NP can be an early symptom of diabetic neuropathy, which is 
pathologically similar to HIV-SN (18). However, the cross-sectional study design precludes assessment 
of causation and the small number of subjects with NP limited our power to assess associations.  
 
The small number participants that were enrolled in this study clearly a limitation and findings 
warrant confirmation. Many patients were unwilling to enroll due to their long waiting times in the 
outpatient clinic and some refused the NCS due to their fear of electrical currents. However we accept 
that patients with symptoms may be more likely to enroll. However we show that HIV patients can 
experience NP without taking stavudine, but PI may be associated with this condition. We provide 
evidence that NP may be an early sign of HIV-SN, and recommend screening for NP and considering 
use of non-PI based ART in affected individuals.  
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Table 1. Univariate analyses linked pain with PI use and a longer duration of ART 
 Neuropathic Pain p 
  No (n=184) Yes (n=13)  
Female gendera 28.8% 30.8% 1.00 
Malay ethnicity  95.1% 92.3% 0.74 
Age (years)b 35.8 + 6 34 + 3.7 0.09 
Height (cm)c 167 (147 – 180) 165 (142-177) 0.58 
Weight (Kg)b 60.4 + 10.5 67.4 + 16.2 0.06 
Weight >65Kga 30% 54% 0.07 
IVDU transmission  36% 38.5% 0.6 
Hepatitis C antibodya 35.3% 30.8% 0.50 
Isoniazid 45.7% 38.5% 0.42 
Declared alcohol use 22.3% 23% 0.59 
>1000 copies HIV RNA/mL 4.3% 15.4% 0.13 
Nadir CD4+ T-cells/ulc 118.5 (1-599) 67 (10-342) 0.54 
Nadir <200 CD4+ T-cells/ula 68% 53.8% 0.23 
Current CD4+ T-cells/ulc 444 (21-1166) 411 (103-658) 0.09 
Current <200 CD4+ T-cells/ula 7.6% 23% 0.09 
BPNST+HIV-SN 12.5% 38.5% 0.02 
Abnormal SSW test 25.5% 53.8% 0.05 
Abnormal NCS 6.5% 0% 0.26 
Current ART regimen 
2 NRTI + 1 NNRTIa 91% 70% 0.036 
2 NRTI + PI 9.2% 30% 
Zidovudinea 86.4% 76.9% 0.28 
Lopinavir/Ritonavir 10.8% 38.4% 0.014 
Nevirapine 71.2% 69.2% 0.55 
Efavirenz 44% 69.2% 0.07 
Tenofovir 32.6% 53.8% 0.11 
Emtricitabine 8.2% 15.4% 0.31 
ART duration (years)c 4.4 (1.1 – 12.7) 1.7 (1 – 6.4) 0.002 
ART duration <2 years a 15.2% 53.8% 0.002 
a categorical data assessed with Fischer’s exact tests 
b mean + standard deviation, assessed with Student’s t tests (parametric data) 
c median (range), assessed with Mann-Whitney tests (non-parametric data) 
 ART= antiretroviral therapy; BPNST+-HIV-SN = HIV sensory neuropathy assessed by BPNST; IVDU = intra-
venous drug user; NCS =nerve conduction study; NNRTI = non nucleoside reverse transcriptase inhibitor; 
NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; SSW = stimulated skin 
wrinkling;  
 
 
 
 
 
 
 
 
Figure 1. The duration of ART in patients with only NP, NP and BPNST+HIV-SN and only 
BPNST+HIV-SN. Horizontal lines represent median and interquartile range.  ART = antiretroviral 
therapy; NP = neuropathic pain; BPNST+HIV-SN = HIV sensory neuropathy assessed by BPNST.   
* p<0.05 (Mann Whitney). 
 
